Evaluation of a Hanging-Breast PET System for Primary Tumor Visualization in Patients With Stage I–III Breast Cancer: Comparison With Standard PET/CT

Teixeira, Suzana C; Rebolleda, J. Ferrer; Koolen, Bas B.; Wesseling, Jelle; Jurado, Raúl Sánchez; Stokkel, Marcel P. M.; Santiago, María del Puig Cózar; Noort, Vincent van der; Rutgers, Emiel J.; Olmos, Renato A. Valdés

doi:10.2214/ajr.15.15371

Cited by 40 publications

(36 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Since that early work, a number of designs for breast PET have emerged, including a couple of commercial systems such as the Oncovision MAMMI design. 57 Despite the improvements in spatial resolution, sensitivity, and specificity offered by these dedicated devices, in practice most centers prefer a whole-body PET scanner that can image all organs.…”

Section: Instrumentation For Positron Emissionmentioning

confidence: 99%

History and future technical innovation in positron emission tomography

2017

View full text Add to dashboard Cite

Abstract. Instrumentation for positron emission tomography (PET) imaging has experienced tremendous improvements in performance over the past 60 years since it was first conceived as a medical imaging modality. Spatial resolution has improved by a factor of 10 and sensitivity by a factor of 40 from the early designs in the 1970s to the high-performance scanners of today. Multimodality configurations have emerged that combine PET with computed tomography (CT) and, more recently, with MR. Whole-body scans for clinical purposes can now be acquired in under 10 min on a state-of-the-art PET/CT. This paper will review the history of these technical developments over 40 years and summarize the important clinical research and healthcare applications that have been made possible by these technical advances. Some perspectives for the future of this technology will also be presented that promise to bring about new applications of this imaging modality in clinical research and healthcare.

show abstract

Section: Instrumentation For Positron Emissionmentioning

confidence: 99%

History and future technical innovation in positron emission tomography

2017

View full text Add to dashboard Cite

show abstract

“…In order to overcome missing lesions close to the pectoral muscle because of compression of the breast, other dedicated breast PET techniques were introduced including MAMmography with Molecular Imaging (MAMMI) PET (Koolen et al, 2012b). MAMMI PET is a high-resolution breast PET for hanging breast molecular imaging, was showed to have higher sensitivity for primary breast cancer lesions within the scanning range of the device, compared to PET/CT (Teixeira et al, 2016). Moreover, MAMMI PET proved to be superior to PET/CT in evaluating heterogeneity of primary tumor (18)F-FDG uptake in breast cancer, offering a rationale for (18)F-FDG-guided biopsies (Koolen et al, 2014).…”

Section: Future Directionsmentioning

confidence: 99%

Positron emission tomography in breast cancer: 18F- FDG and other radiopharmaceuticals

Iakovou

Giannoula

Gkantaifi

et al. 2018

European J Hybrid Imaging

View full text Add to dashboard Cite

Background: Breast cancer heterogeneity reflects the complex biology of this disease. Breast cancer subtypes, as identified either by immunohistochemistry (IHC) or by gene expression analysis, present different molecular characteristics and prognosis. In this context, molecular imaging techniques providing functional information, contribute in evaluating response to treatment and long-term prognosis among different subtypes. Nuclear imaging diagnosis modalities play an important role for conducting research on cancer biology and developing new treatment approaches. Positron Emission Tomography (PET) is a radionuclide based imaging method that has the potential to locate the tumor, define its staging, and monitor its response to treatment.Results: In the current study, we will review the utility of the most widely used molecular imaging technique, 18 F-fluorodeoxyglucose ( 18 F-FDG) PET, in order to determine the relationship between standardized uptake values (SUVs) and immunohistopathological factors, as well as to clarify whether PET is able to predict breast cancer phenotypes. Moreover, we will discuss the rising development of new radiopharmaceuticals in PET imaging, such as 18 F-fluoro-17-estradiol (FES), 18 F-fluoro-l-thymidine (FLT), 18 F-fluoromisonidazole (FISO), and 89 Zr-immuno-PET, which give more information about tumor characteristics. Conclusions: In order to improve clinical decision making, enabling hereafter more successful individualized therapies, it is imperative to combine PET radiopharmaceuticals and imaging techniques of critical biologic and pathologic phenomena, including ER, PR and HER2 expression, angiogenesis, hypoxia, apoptosis and metabolic changes in the microenviroment of breast tumors. BackgroundBreast cancer is the most frequently diagnosed noncutaneous malignancy in women worldwide, accounting for approximately 30% of all new cancer diagnoses and about 14% of all cancer deaths in women. About 63,410 new cases of female breast carcinoma in situ and 252,710 new cases of invasive breast cancer will be diagnosed in 2017 among United States (US) women. It is estimated that one in eight women will develop breast cancer during their life, while it is the second most common cause of cancer

show abstract

“…11,12) The diagnostic capability of db-PET in breast cancer has been reported previously. 13,14) We introduced db-PET with a ring-type scanner for hanging breast imaging (MAMMI, Oncovision, Valencia, Spain) for the detection and diagnosis of breast cancer. However, the potential of db-PET has not yet been established, and there has been no report of the application of db-PET on an Oncovision device in Japan.…”

Section: Radioisotopesmentioning

confidence: 99%

“…When the lesion was included in the FOV of db-PET, it could be clearly visualized, but when located outside the FOV, it was difficult to detect 20% of lesions, which was somewhat higher than previously reported. 13) This may be due to racial differences, as a previous study had reported that Japanese women have breast that are characteristically denser and smaller than those of Caucasian women. 23, 24) This issue of falling outside the scan range of db-PET should be addressed to allow visualization of the most dorsal breast lesions.…”

Section: Study Limitationmentioning

confidence: 99%

The Potential of Dedicated Breast PET with a Ring-type Scanner—Basic Evaluation and Clinical Experience—

Mitsumoto

Uno²,

Irie³

et al. 2018

RADIOISOTOPES

View full text Add to dashboard Cite

In breast cancer, the survival rate is related to the size of the lesion. Since the spatial resolution of wholebody (WB)-PET is limited, it is difficult to evaluate small cancerous lesions. To improve resolution, highresolution dedicated breast PET (db-PET) scanners have been developed. However, the potential of db-PEThas not yet been established, and there has been no report of the application of db-PET on an Oncovision device (MAMMI) in breast cancer cases in Japan.The purpose of this study was to evaluate the potential of db-PET for assessing breast cancer. The influence of image reconstruction parameters was verified in a phantom evaluation, while we quantitatively investigated the ability of dB-PET to detect tumors, in comparison with WB-PET, with patients in the prone position, in a clinical evaluation. Despite a limited field of view in the vicinity of the chest wall, we show that db-PET has markedly better clinical value for diagnosing breast cancer as compared to WB-PET.

show abstract

Evaluation of a Hanging-Breast PET System for Primary Tumor Visualization in Patients With Stage I–III Breast Cancer: Comparison With Standard PET/CT

Abstract: Although in an overall evaluation MAMMI-PET was not superior to PET/CT, MAMMI-PET does have higher sensitivity for primary breast cancer lesions within the scanning range of the device. Optimization of the positioning device may increase visualization of the most dorsal lesions.

Cited by 40 publications

References 35 publications

History and future technical innovation in positron emission tomography

History and future technical innovation in positron emission tomography

Positron emission tomography in breast cancer: 18F- FDG and other radiopharmaceuticals

The Potential of Dedicated Breast PET with a Ring-type Scanner—Basic Evaluation and Clinical Experience—

Contact Info

Product

Resources

About